Bank Julius Baer & Co. Ltd, Zurich Alnylam Pharmaceuticals, Inc. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

  • $25.6 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

May 16, 2024
SELL
$151.41 - $196.57 $34,521 - $44,817
-228 Reduced 9.5%
2,172 $415,000
Q4 2023

May 16, 2024
BUY
$151.41 - $196.57 $363,384 - $471,768
2,400 New
2,400 $459,000
Q4 2023

Feb 02, 2024
BUY
$151.41 - $196.57 $328,862 - $426,950
2,172 New
2,172 $416,000

Others Institutions Holding ALNY

# of Institutions
644
Shares Held
109M
Call Options Held
1.28M
Put Options Held
1.21M
View Full List

About ALNYLAM PHARMACEUTICALS, INC.

ALNY Quotes by TradingView
  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $28.8B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Bank Julius Baer & Co. Ltd, Zurich Portfolio

Follow Bank Julius Baer & Co. Ltd, Zurich and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

News

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email